Abstract
Iron deficiency severely limits the efficacy of recombinant human erythropoietin (EPO). In order to determine how best to identify and monitor children at risk of developing iron deficiency, we serially measured several parameters of iron status in nine children before and during a 24-week period of EPO therapy. Serum ferritin was the best predictor of development of iron deficiency, five of the nine children developed iron deficiency, characterised by a poor haemoglobin response or evidence of microcytosis and hypochromia; all had a serum ferritin of 60 μg/l or less at the start of EPO. Haemoglobin response was also related to change in mean red cell volume (MCV); a falling MCV, irrespective of absolute value, accompanying a poor response to EPO. Iron treatment in five children resulted in significant improvements in haemoglobin and iron status parameters. Although MCV remained low, there was a marked increase in red cell volume distribution width after iron, which may be of value in monitoring the response to iron therapy. We suggest that children with a serum ferritin of 60 μg/l or less and those who develop a falling MCV during EPO treatment should receive high-dose oral iron supplementation before and during treatment with EPO.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adamson JW, Eschbach JW, Finch CA (1968) The kidney and erythropoiesis. Am J Med 44: 725–733
Eschbach JW, Cook JD, Finch CA (1970) Iron absorption in chronic renal disease. Clin Sci 38: 191–196
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin: results of a phase I and II clinical trial. N Engl J Med 316: 73–78
Sinai-Trieman L, Salusky IB, Fine RN (1989) Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 114: 550–554
Macdougall IC, Davies ME, Hutton RD, Cavill I, Lewis NP, Coles GA, Williams JD (1990) The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 5: 950–955
Eschbach JW, Abdulhadi MH, Browne JK, Delano MD, Downing M, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley R, Korbet S, Krantz SB, Lundin P, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III, multicenter clinical trial. Ann Intern Med 111: 992–1000
Casati S, Castelnovo C, Campise M, Ponticelli C (1990) Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin. Nephrol Dial Transplant 5: 441–443
Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA (1989) Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35: 712–716
Slimes MA, Addiego JE Jr, Dallmann PR (1974) Ferritin in serum: diagnosis of iron deficiency and iron overload in infants and children. Blood 43: 581–590
Report on health and social subjects 41 (1992) Dietary reference values for food energy and nutrients for the United Kingdom. Department of Health, HMSO, pp 161–166
Rigden SPA, Montini G, Morris M, Clark KGA, Haycock GB, Chantler C, Hill RC (1990) Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatr Nephrol 4: 618–622
Ellis D (1979) Serum ferritin compared with other indices of iron status in children and teenagers undergoing maintenance haemodialysis. Clin Chem 25: 741–744
Lipschitz DA, Cook JD, Finch CA (1974) A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 290: 1213–1216
Fervenza F, Oliver DO, Forman E, Winearls CG (1989) Autonomous hyperparathyroidism does not cause resistance to recombinant human erythropoietin (abstract). Nephrol Dial Transplant 4: 472–473
McGonigle RJS, Wallin JD, Husserl F, Deftos JL, Rice JC, O'Neill WH, Fisher JW (1984) Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anaemia of renal failure. J Lab Clin Med 104: 1016–1026
Blumberg AB, Marti HRM, Graber CG (1983) Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis. JAMA 250: 3317–3319
Cavill I (1982) Diagnostic methods. Clinics in Haematology, 11: 259–275
Macdougall IC, Hutton RD, Cavill I, Cloes GA, Williams JD (1989) Poor response to treatment of renal anaemia with erythropoletin corrected by iron given intravenously. BMJ 299: 157–158
Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD (1992) Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 304: 225–226
Davidson RSL, Hamilton PJ (1978) High mean red cell volume: its incidence and significance in routine haematology. J Clin Pathol 31: 493–498
Bessman JD, Gilmer PR, Gardner FH (1983) Improved classification of anemias by MCV and RDW. Am J Clin Pathol 80: 322–326
Hamstra RD, Block MH, Schocket AL (1980) Intravenous iron dextran in clinical medicine. JAMA 243: 1726–1731
Allegra V, Mengozzi G, Vasile A (1991) Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 57: 175–182
Muller-Wiefel DE, Waldherr R, Feist D, Kaick G van (1984) The assessment of iron stores in children on regular dialysis treatment. Contrib Nephrol 38: 141–152
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morris, K.P., Watson, S., Reid, M.M. et al. Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use?. Pediatr Nephrol 8, 51–56 (1994). https://doi.org/10.1007/BF00868261
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00868261